Executive VP of Discovery
Andrew leads BIOAGE's drug discovery programs from new target identification through preclinical development and beyond. As a member of the executive team he helps shape company strategy in collaboration with company leadership and external advisory board members. With >10 years in the Pharmaceutical and Biotech Industry at Abbott/AbbVie and Ardelyx, Andrew is experienced across Drug Discovery and Development stages including new target discovery and validation, hit-to-lead and lead optimization, clinical candidate selection, non-clinical development and translational strategies. Andrew has contributed to the nomination of clinical candidates across multiple therapeutic areas in various roles from project leader, functional area head, toxicology and safety pharmacology. Andrew received his PhD in pharmacology from Michigan State University and completed training in Veterinary Medicine and Surgery at Murdoch University in Australia.